6α-hydroxy Paclitaxel – 500 µg

Brand:
Cayman
CAS:
153212-75-0
Storage:
-20
UN-No:
Non-Hazardous - /

6α-hydroxy Paclitaxel is a primary metabolite of the anticancer compound paclitaxel (Item No. 10461), produced by the action of the cytochrome P450 isoform CYP2C8.{14232,24033} The generation of 6α-hydroxy paclitaxel by CYP2C8 can be impacted by other drugs (e.g., fluvastatin, Item No. 10010334) or dietary components that interefere with CYP2C8 activity, as well as by CYP2C8 genetic polymorphisms.{24032,24031,24030}  

 

Available on backorder

SKU: 10009027 - 500 µg Category:

Description

A primary metabolite of the anti-cancer compound paclitaxel, produced by the action of the CYP450 isoform CYP2C8


Formal name: βS-(benzoylamino)-αR-hydroxy-(2aR,3S,4R,4aS,6R,9S,11S,12S,12aR,12bS,)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-3,4,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester-benzenepropanoic acid

Synonyms:  ​6α-hydroxy Taxo​l

Molecular weight: 869.9

CAS: 153212-75-0

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Xenobiotic Metabolites||Research Area|Cancer|Cell Cycle|G1||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|p53 Signaling||Research Area|Cancer|Transcription Factors|p53||Research Area|Toxicology|Drug Metabolism|Cytochrome P450||Research Area|Toxicology|Drug Metabolism|Drug Metabolites